Trial · NCT06221501
Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
NCT06221501, Phase 2, Not yet recruiting, Shanghai Zhongshan Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Perioperative Efgartigimod for Thymoma and Myasthenia Gravis. Trials, record NCT06221501. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06221501
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
- NCT number
- NCT06221501
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Shanghai Zhongshan Hospital
- Conditions
- Myasthenia Gravis
- Interventions
- Efgartigimod Alfa
- First posted
- 2024-01-24
- Last updated
- 2024-01-24
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of the activity of daily living (ADL) score at the fourth visit from the baseline visit (first visit) | Baseline and 3 weeks after the first visit. | The value was calculated by the ADL score at the fourth visit minus the ADL score at the first visit (baseline). |
| Secondary | Change of the ADL score at the second visit from the baseline visit (first visit) | Baseline and 1 day before surgery (always at the 1 week after the first visit). | The value was calculated by the ADL score at the second visit minus the ADL score at the first visit (baseline). |
| Secondary | Change of quantitative myasthenia gravis (QMG) score at the second visit from the baseline visit (first visit) | Baseline and 1 day before surgery (always at the 1 week after the first visit). | The value was calculated by the QMG score at the second visit minus the QMG score at the first visit (baseline). |
| Secondary | Change of myasthenia gravis composite (MGC) score at the second visit from the baseline visit (first visit) | Baseline and 1 day before surgery (always at the 1 week after the first visit). | The value was calculated by the MGC score at the second visit minus the MGC score at the first visit (baseline). |
| Secondary | Change of QMG score at the fourth visit from the baseline visit (first visit) | Baseline and 3 weeks after the first visit. | The value was calculated by the QMG score at the fourth visit minus the QMG score at the first visit (baseline). |
| Secondary | Change of MGC score at the fourth visit from the baseline visit (first visit) | Baseline and 3 weeks after the first visit. | The value was calculated by the MGC score at the fourth visit minus the MGC score at the first visit (baseline). |
| Secondary | Change of lgG-AChR level at the fourth visit from the baseline visit (first visit) | Baseline and 3 weeks after the first visit. | The value (percent) was calculated by the lgG-AChR level at the fourth visit minus the lgG-AChR level score at the first visit (baseline). |
| Secondary | The rate of postoperative myasthenia crisis | From the day when trial begin to the day when the follow-up is ended. Up to 48 weeks. | |
| Secondary | Postoperative hospital stay | From the day when trial begin to the day when the follow-up is ended. Up to 48 weeks. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40320172 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06221501
GET https://conductscience.org/api/trials/v1/NCT06221501/registered